RV
Live price temporarily unavailable.
Price history
Revolution Medicines (RVMD) is a Health Care company in the Russell 1000. Latest news and coverage below.
IPO: February 13, 2020 · $17.00 offering · NASDAQ · View IPO details →
Revolution Medicines revenue & net income history (FY2018–FY2025)
RevenueNet income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $20.2M | $50.0M | $43.0M | $29.4M | $35.4M | $11.6M | $0 | $0 |
| Growth (year over year) | — | +148.2% | −14.1% | −31.6% | +20.4% | −67.3% | −100.0% | — |
| Operating income | −$40.3M | −$54.1M | −$110.7M | −$188.0M | −$258.3M | −$487.2M | −$689.5M | −$1.18B |
| Operating margin | −200.0% | −108.2% | −257.5% | −639.7% | −730.0% | −4207.1% | — | — |
| Net income | −$41.8M | −$47.7M | −$108.2M | −$187.1M | −$248.7M | −$436.4M | −$600.1M | −$1.13B |
| Net margin | −207.2% | −95.2% | −251.6% | −636.6% | −703.0% | −3768.3% | — | — |
| EPS (diluted) | −$21.24 | −$22.33 | −$2.01 | −$2.57 | −$3.08 | −$3.86 | −$3.58 | −$5.95 |
| Balance sheet | ||||||||
| Cash and equivalents | $69.6M | $16.7M | $104.3M | $108.5M | $161.4M | $696.1M | $543.1M | $383.7M |
| Total assets | — | $220.5M | $567.4M | $738.0M | $811.9M | $2.06B | $2.56B | $2.35B |
| Total liabilities | — | $68.0M | $92.7M | $135.4M | $126.7M | $235.5M | $293.1M | $723.2M |
| Shareholders' equity | −$108.4M | −$152.6M | $474.7M | $602.6M | $685.2M | $1.83B | $2.27B | $1.63B |
| Cash flow | ||||||||
| Operating cash flow | $1.21M | −$49.6M | −$100.1M | −$147.2M | −$224.4M | −$350.6M | −$557.4M | −$897.7M |
| Capital expenditure | $1.50M | $2.59M | $2.93M | $6.53M | $10.8M | $7.73M | $10.3M | $16.0M |
| Free cash flow | −$286.0K | −$52.2M | −$103.0M | −$153.7M | −$235.2M | −$358.3M | −$567.7M | −$913.7M |
| Dividends paid | — | — | $0 | — | — | — | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Operating income | −$175.7M | — | −$240.8M | −$264.7M | −$315.3M | −$361.6M | −$445.2M | −$505.1M |
| Net income | −$156.3M | — | −$213.4M | −$247.8M | −$305.2M | −$364.9M | −$453.8M | −$644.4M |
| EPS (diluted) | −$0.94 | — | −$1.13 | −$1.31 | −$1.61 | −$1.90 | −$2.29 | −$3.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $201.3M | $543.1M | $333.6M | $402.4M | $217.4M | $383.7M | $440.9M | $815.4M |
| Total assets | $1.76B | $2.56B | $2.37B | $2.43B | $2.25B | $2.35B | $2.25B | $4.32B |
| Total liabilities | $196.7M | $293.1M | $287.2M | $564.2M | $655.0M | $723.2M | $753.8M | $1.72B |
| Shareholders' equity | $1.57B | $2.27B | $2.08B | $1.87B | $1.60B | $1.63B | $1.50B | $2.61B |
| Cash flow | ||||||||
| Operating cash flow | −$130.4M | — | −$194.4M | −$221.8M | −$207.3M | −$274.2M | −$354.2M | −$387.3M |
| Capital expenditure | $3.52M | — | $3.27M | $7.45M | $3.35M | $1.93M | $1.54M | $2.29M |
| Free cash flow | −$133.9M | — | −$197.7M | −$229.2M | −$210.7M | −$276.2M | −$355.7M | −$389.6M |
From Revolution Medicines's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Revolution Medicines
- Headquarters
- Redwood City, California From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with RVMD
- RNAZ TransCode Therapeutics
- RNXT RenovoRx
- ROIV Roivant Sciences
- RPRX Royalty Pharma
- RXRX Recursion Pharmaceuticals Inc Clas
- RXST Rxsight Inc
- RYTM Rhythm Pharmaceuticals Inc
- RZLT Rezolute Inc